Copyright Reports & Markets. All rights reserved.

Global and Japan Dementia and Movement Disorder Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Dementia and Movement Disorder Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 MAO inhibitors (monoamine oxidase)
    • 1.2.3 AChE inhibitors (acetylcholinesterase)
    • 1.2.4 Glutamate inhibitors
  • 1.3 Market by Application
    • 1.3.1 Global Dementia and Movement Disorder Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Branded drugs
    • 1.3.3 Generic drugs
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Dementia and Movement Disorder Treatment Market Perspective (2015-2026)
  • 2.2 Global Dementia and Movement Disorder Treatment Growth Trends by Regions
    • 2.2.1 Dementia and Movement Disorder Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Dementia and Movement Disorder Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Dementia and Movement Disorder Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Dementia and Movement Disorder Treatment Players by Market Size
    • 3.1.1 Global Top Dementia and Movement Disorder Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Dementia and Movement Disorder Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Dementia and Movement Disorder Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Dementia and Movement Disorder Treatment Revenue
  • 3.4 Global Dementia and Movement Disorder Treatment Market Concentration Ratio
    • 3.4.1 Global Dementia and Movement Disorder Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Dementia and Movement Disorder Treatment Revenue in 2019
  • 3.5 Key Players Dementia and Movement Disorder Treatment Area Served
  • 3.6 Key Players Dementia and Movement Disorder Treatment Product Solution and Service
  • 3.7 Date of Enter into Dementia and Movement Disorder Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Dementia and Movement Disorder Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Dementia and Movement Disorder Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Dementia and Movement Disorder Treatment Forecasted Market Size by Type (2021-2026)

5 Dementia and Movement Disorder Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Dementia and Movement Disorder Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Dementia and Movement Disorder Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Dementia and Movement Disorder Treatment Market Size (2015-2026)
  • 6.2 North America Dementia and Movement Disorder Treatment Market Size by Type (2015-2020)
  • 6.3 North America Dementia and Movement Disorder Treatment Market Size by Application (2015-2020)
  • 6.4 North America Dementia and Movement Disorder Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Dementia and Movement Disorder Treatment Market Size (2015-2026)
  • 7.2 Europe Dementia and Movement Disorder Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Dementia and Movement Disorder Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Dementia and Movement Disorder Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Dementia and Movement Disorder Treatment Market Size (2015-2026)
  • 8.2 China Dementia and Movement Disorder Treatment Market Size by Type (2015-2020)
  • 8.3 China Dementia and Movement Disorder Treatment Market Size by Application (2015-2020)
  • 8.4 China Dementia and Movement Disorder Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Dementia and Movement Disorder Treatment Market Size (2015-2026)
  • 9.2 Japan Dementia and Movement Disorder Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Dementia and Movement Disorder Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Dementia and Movement Disorder Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Dementia and Movement Disorder Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Dementia and Movement Disorder Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Dementia and Movement Disorder Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Dementia and Movement Disorder Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Allergan
    • 11.1.1 Allergan Company Details
    • 11.1.2 Allergan Business Overview
    • 11.1.3 Allergan Dementia and Movement Disorder Treatment Introduction
    • 11.1.4 Allergan Revenue in Dementia and Movement Disorder Treatment Business (2015-2020))
    • 11.1.5 Allergan Recent Development
  • 11.2 Eisai
    • 11.2.1 Eisai Company Details
    • 11.2.2 Eisai Business Overview
    • 11.2.3 Eisai Dementia and Movement Disorder Treatment Introduction
    • 11.2.4 Eisai Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.2.5 Eisai Recent Development
  • 11.3 Novartis
    • 11.3.1 Novartis Company Details
    • 11.3.2 Novartis Business Overview
    • 11.3.3 Novartis Dementia and Movement Disorder Treatment Introduction
    • 11.3.4 Novartis Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.3.5 Novartis Recent Development
  • 11.4 Teva Pharmaceutical Industries
    • 11.4.1 Teva Pharmaceutical Industries Company Details
    • 11.4.2 Teva Pharmaceutical Industries Business Overview
    • 11.4.3 Teva Pharmaceutical Industries Dementia and Movement Disorder Treatment Introduction
    • 11.4.4 Teva Pharmaceutical Industries Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.4.5 Teva Pharmaceutical Industries Recent Development
  • 11.5 Amgen
    • 11.5.1 Amgen Company Details
    • 11.5.2 Amgen Business Overview
    • 11.5.3 Amgen Dementia and Movement Disorder Treatment Introduction
    • 11.5.4 Amgen Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.5.5 Amgen Recent Development
  • 11.6 Pfizer
    • 11.6.1 Pfizer Company Details
    • 11.6.2 Pfizer Business Overview
    • 11.6.3 Pfizer Dementia and Movement Disorder Treatment Introduction
    • 11.6.4 Pfizer Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.6.5 Pfizer Recent Development
  • 11.7 UCB
    • 11.7.1 UCB Company Details
    • 11.7.2 UCB Business Overview
    • 11.7.3 UCB Dementia and Movement Disorder Treatment Introduction
    • 11.7.4 UCB Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.7.5 UCB Recent Development
  • 11.8 H. Lundbeck
    • 11.8.1 H. Lundbeck Company Details
    • 11.8.2 H. Lundbeck Business Overview
    • 11.8.3 H. Lundbeck Dementia and Movement Disorder Treatment Introduction
    • 11.8.4 H. Lundbeck Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.8.5 H. Lundbeck Recent Development
  • 11.9 F. Hoffmann-La Roche
    • 11.9.1 F. Hoffmann-La Roche Company Details
    • 11.9.2 F. Hoffmann-La Roche Business Overview
    • 11.9.3 F. Hoffmann-La Roche Dementia and Movement Disorder Treatment Introduction
    • 11.9.4 F. Hoffmann-La Roche Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.9.5 F. Hoffmann-La Roche Recent Development
  • 11.10 Eli Lilly
    • 11.10.1 Eli Lilly Company Details
    • 11.10.2 Eli Lilly Business Overview
    • 11.10.3 Eli Lilly Dementia and Movement Disorder Treatment Introduction
    • 11.10.4 Eli Lilly Revenue in Dementia and Movement Disorder Treatment Business (2015-2020)
    • 11.10.5 Eli Lilly Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Dementia and Movement Disorder Treatment Scope and Market Size
    Dementia and Movement Disorder Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dementia and Movement Disorder Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    MAO inhibitors (monoamine oxidase)
    AChE inhibitors (acetylcholinesterase)
    Glutamate inhibitors

    Market segment by Application, split into
    Branded drugs
    Generic drugs

    Based on regional and country-level analysis, the Dementia and Movement Disorder Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Dementia and Movement Disorder Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Allergan
    Eisai
    Novartis
    Teva Pharmaceutical Industries
    Amgen
    Pfizer
    UCB
    H. Lundbeck
    F. Hoffmann-La Roche
    Eli Lilly

    Buy now